Nackers Fabienne, Cohuet Sandra, le Polain de Waroux Olivier, Langendorf Céline, Nyehangane Dan, Ndazima Donny, Nanjebe Deborah, Karani Angela, Tumwesigye Elioda, Mwanga-Amumpaire Juliet, Scott J Anthony G, Grais Rebecca F
Epicentre, 8 rue Saint Sabin, 75011 Paris, France.
Epicentre, 8 rue Saint Sabin, 75011 Paris, France.
Vaccine. 2017 Sep 18;35(39):5271-5277. doi: 10.1016/j.vaccine.2017.07.081. Epub 2017 Aug 4.
Information on Streptococcus pneumoniae nasopharyngeal (NP) carriage before the pneumococcal conjugate vaccine (PCV) introduction is essential to monitor impact. The 10-valent PCV (PCV10) was officially introduced throughout Ugandan national childhood immunization programs in 2013 and rolled-out countrywide during 2014. We aimed to measure the age-specific Streptococcus pneumoniae carriage and serotype distribution across all population age groups in the pre-PCV10 era in South Western Uganda.
We conducted a two-stage cluster, age-stratified, cross-sectional community-based study in Sheema North sub-district between January and March 2014. One NP swab was collected and analyzed for each participant in accordance with World Health Organization guidelines.
NP carriage of any pneumococcal serotype was higher among children <2years old (77%; n=387) than among participants aged ≥15years (8.5%; n=325) (chi p<0.001). Of the 623 positive cultures, we identified 49 serotypes among 610 (97.9%) isolates; thirteen (2.1%) isolates were non-typeable. Among <2years old, serotypes 6A, 6B, 14, 15B, 19F and 23F accounted for half of all carriers. Carriage prevalence with PCV10 serotypes was 29.4% among individuals aged <2years (n=387), 23.4% in children aged 2-4years (n=217), 11.4% in 5-14years (n=417), and 0.4% among individuals ≥15years of age (n=325). The proportion of carried pneumococci serotypes contained in PCV10 was 38.1% (n=291), 32.8% (n=154), 29.4% (n=156), and 4.4% (n=22) among carriers aged <2years, 2-4years, 5-14years and ≥15years, respectively.
In Sheema district, the proportion of PCV10 serotypes was low (<40%), across all age groups, especially among individuals aged 15years or older (<5%). PCV10 introduction is likely to impact transmission among children and to older individuals, but less likely to substantially modify pneumococcal NP ecology among individuals aged 15years or older.
在引入肺炎球菌结合疫苗(PCV)之前,有关肺炎链球菌鼻咽部(NP)携带情况的信息对于监测其影响至关重要。10价肺炎球菌结合疫苗(PCV10)于2013年在乌干达全国儿童免疫规划中正式引入,并于2014年在全国范围内推广。我们旨在测量乌干达西南部PCV10时代所有年龄组中特定年龄的肺炎链球菌携带情况和血清型分布。
2014年1月至3月,我们在希马北区进行了一项两阶段整群、按年龄分层的基于社区的横断面研究。按照世界卫生组织的指南,为每位参与者采集一份NP拭子并进行分析。
2岁以下儿童中任何肺炎球菌血清型的NP携带率(77%;n = 387)高于15岁及以上参与者(8.5%;n = 325)(卡方检验p<0.001)。在623份阳性培养物中,我们在610份(97.9%)分离株中鉴定出49种血清型;13份(2.1%)分离株无法分型。在2岁以下儿童中,6A、6B、14、15B、19F和23F血清型占所有携带者的一半。PCV10血清型的携带率在2岁以下个体中为29.4%(n = 387),2 - 4岁儿童中为23.4%(n = 217),5 - 14岁儿童中为11.4%(n = 417),15岁及以上个体中为0.4%(n = 325)。在2岁以下、2 - 4岁、5 - 14岁和15岁及以上的携带者中,PCV10中包含的肺炎球菌血清型比例分别为38.1%(n = 291)、32.8%(n = 154)、29.4%(n = 156)和4.4%(n = 22)。
在希马区,所有年龄组中PCV10血清型的比例都很低(<40%),尤其是在15岁及以上个体中(<5%)。引入PCV10可能会影响儿童之间以及向年长者的传播,但不太可能实质性改变15岁及以上个体中的肺炎球菌NP生态。